TY  - CONF
AU  - Vuković, Miodrag
AU  - Filipović, Lidija
AU  - Popović, Milica
AU  - Petrović, Nina
AU  - Tanić, Miljana
AU  - Janković, Radmila
AU  - Korać, Aleksandra
AU  - Čavić, Milena
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12502
AB  - Introduction: The incidence of lung cancer (LC) in Serbia has increased over the last three decades. Up to 40% of patients with advanced non-small cell lung cancer (NSCLC) develop pleural effusion (PE). The aim of this study was to evaluate the usability of existing methods for isolation of extracellular vesicles from PE samples of patients with advanced non-small cell lung cancer and to characterize them for further use in the clinical/diagnostic/research setting. Material & Methods: PE samples diluted in PBS (1:1) from patients with advanced NSCLC were used. In-house spherical porous methacrylate-based copolymer coupled with VHH antibodies was used for the isolation of extracellular vesicles (EV) from PE samples. Flow-cytometry was performed for detection of exosomal markers. Results: A pool of PE was prepared from 5 patients with advanced NSCLC. Flow cytometry confirmed that the isolation of EVs was successful using the in-house affinity chromatography method. The presence of CD9 antigen was detected, as well as a decrease in the signal after the addition of Triton X-100. Further plans include the analysis of CD63 and CD81 antigens using flow cytometry, NTA analysis to determine the number and diameter of obtained vesicles, as well as TEM and SEM to determine their morphology. Discussion: We aim to investigate for the first time whether this method is applicable to pleural effusion samples as a new cancer liquid biopsy sample type. We also plan to evaluate the method in comparison with a commercial isolation kit.
PB  - Serbian Society for Extracellular Vesicles (SrbEVs)
PB  - Austrian Society for Extracellular Vesicles (ASEV)
PB  - Hungarian Society for Extracellular Vesicles (HSEV)
PB  - Slovenian Network for Extracellular Vesicles (SiN-EV)
C3  - Small New World 2.0 : Book of abstracts
T1  - Isolation and characterization of extracellular vesicles from pleural effusion samples of patients with advanced non-small cell lung cancer
SP  - 51
EP  - 51
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12502
ER  - 

@conference{
author = "Vuković, Miodrag and Filipović, Lidija and Popović, Milica and Petrović, Nina and Tanić, Miljana and Janković, Radmila and Korać, Aleksandra and Čavić, Milena",
year = "2023",
abstract = "Introduction: The incidence of lung cancer (LC) in Serbia has increased over the last three decades. Up to 40% of patients with advanced non-small cell lung cancer (NSCLC) develop pleural effusion (PE). The aim of this study was to evaluate the usability of existing methods for isolation of extracellular vesicles from PE samples of patients with advanced non-small cell lung cancer and to characterize them for further use in the clinical/diagnostic/research setting. Material & Methods: PE samples diluted in PBS (1:1) from patients with advanced NSCLC were used. In-house spherical porous methacrylate-based copolymer coupled with VHH antibodies was used for the isolation of extracellular vesicles (EV) from PE samples. Flow-cytometry was performed for detection of exosomal markers. Results: A pool of PE was prepared from 5 patients with advanced NSCLC. Flow cytometry confirmed that the isolation of EVs was successful using the in-house affinity chromatography method. The presence of CD9 antigen was detected, as well as a decrease in the signal after the addition of Triton X-100. Further plans include the analysis of CD63 and CD81 antigens using flow cytometry, NTA analysis to determine the number and diameter of obtained vesicles, as well as TEM and SEM to determine their morphology. Discussion: We aim to investigate for the first time whether this method is applicable to pleural effusion samples as a new cancer liquid biopsy sample type. We also plan to evaluate the method in comparison with a commercial isolation kit.",
publisher = "Serbian Society for Extracellular Vesicles (SrbEVs), Austrian Society for Extracellular Vesicles (ASEV), Hungarian Society for Extracellular Vesicles (HSEV), Slovenian Network for Extracellular Vesicles (SiN-EV)",
journal = "Small New World 2.0 : Book of abstracts",
title = "Isolation and characterization of extracellular vesicles from pleural effusion samples of patients with advanced non-small cell lung cancer",
pages = "51-51",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12502"
}

Vuković, M., Filipović, L., Popović, M., Petrović, N., Tanić, M., Janković, R., Korać, A.,& Čavić, M.. (2023). Isolation and characterization of extracellular vesicles from pleural effusion samples of patients with advanced non-small cell lung cancer. in Small New World 2.0 : Book of abstracts
Serbian Society for Extracellular Vesicles (SrbEVs)., 51-51.
https://hdl.handle.net/21.15107/rcub_vinar_12502

Vuković M, Filipović L, Popović M, Petrović N, Tanić M, Janković R, Korać A, Čavić M. Isolation and characterization of extracellular vesicles from pleural effusion samples of patients with advanced non-small cell lung cancer. in Small New World 2.0 : Book of abstracts. 2023;:51-51.
https://hdl.handle.net/21.15107/rcub_vinar_12502 .

Vuković, Miodrag, Filipović, Lidija, Popović, Milica, Petrović, Nina, Tanić, Miljana, Janković, Radmila, Korać, Aleksandra, Čavić, Milena, "Isolation and characterization of extracellular vesicles from pleural effusion samples of patients with advanced non-small cell lung cancer" in Small New World 2.0 : Book of abstracts (2023):51-51,
https://hdl.handle.net/21.15107/rcub_vinar_12502 .

TY  - JOUR
AU  - Srdić-Rajić, Tatjana
AU  - Nikolić, Katarina M.
AU  - Čavić, Milena R.
AU  - Đokić, Ivana
AU  - Gemović, Branislava S.
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/884
AB  - Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signaling in hematologic malignancies and to search for medicinally active agents. (C) 2015 Elsevier B.V. All rights reserved.
PB  - Elsevier
T2  - European Journal of Pharmaceutical Sciences
T1  - Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells
VL  - 81
SP  - 172
EP  - 180
DO  - 10.1016/j.ejps.2015.10.017
ER  - 

@article{
author = "Srdić-Rajić, Tatjana and Nikolić, Katarina M. and Čavić, Milena R. and Đokić, Ivana and Gemović, Branislava S. and Perović, Vladimir R. and Veljković, Nevena V.",
year = "2016",
abstract = "Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signaling in hematologic malignancies and to search for medicinally active agents. (C) 2015 Elsevier B.V. All rights reserved.",
publisher = "Elsevier",
journal = "European Journal of Pharmaceutical Sciences",
title = "Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells",
volume = "81",
pages = "172-180",
doi = "10.1016/j.ejps.2015.10.017"
}

Srdić-Rajić, T., Nikolić, K. M., Čavić, M. R., Đokić, I., Gemović, B. S., Perović, V. R.,& Veljković, N. V.. (2016). Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. in European Journal of Pharmaceutical Sciences
Elsevier., 81, 172-180.
https://doi.org/10.1016/j.ejps.2015.10.017

Srdić-Rajić T, Nikolić KM, Čavić MR, Đokić I, Gemović BS, Perović VR, Veljković NV. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. in European Journal of Pharmaceutical Sciences. 2016;81:172-180.
doi:10.1016/j.ejps.2015.10.017 .

Srdić-Rajić, Tatjana, Nikolić, Katarina M., Čavić, Milena R., Đokić, Ivana, Gemović, Branislava S., Perović, Vladimir R., Veljković, Nevena V., "Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells" in European Journal of Pharmaceutical Sciences, 81 (2016):172-180,
https://doi.org/10.1016/j.ejps.2015.10.017 . .